838 related articles for article (PubMed ID: 27079249)
1. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
[TBL] [Abstract][Full Text] [Related]
2. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.
Earp JC; Mehrotra N; Peters KE; Fiorentino RP; Griebel D; Lee SC; Mulberg A; Röhss K; Sandström M; Taylor A; Tornøe CW; Wynn EL; Van der Walt JS; Garnett C
J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):272-277. PubMed ID: 27875488
[TBL] [Abstract][Full Text] [Related]
3. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
Vinks AA; Emoto C; Fukuda T
Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
[TBL] [Abstract][Full Text] [Related]
4. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
5. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.
Kimura K; Yoshida A; Takayanagi R; Yamada Y
Biopharm Drug Dispos; 2018 Jun; 39(6):283-288. PubMed ID: 29790586
[TBL] [Abstract][Full Text] [Related]
7. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics.
Miyagi SJ; Long-Boyle JR
Drug Metab Lett; 2015; 9(2):80-7. PubMed ID: 26031462
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM
Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614
[TBL] [Abstract][Full Text] [Related]
9. Individualizing the use of medications in children: making Goldilocks happy.
Leeder JS; Brown JT; Soden SE
Clin Pharmacol Ther; 2014 Sep; 96(3):304-6. PubMed ID: 24926777
[TBL] [Abstract][Full Text] [Related]
10. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data.
Rodrigues C; Chiron C; Ounissi M; Dulac O; Gaillard S; Nabbout R; Jullien V
Epilepsy Res; 2019 Feb; 150():38-45. PubMed ID: 30639958
[TBL] [Abstract][Full Text] [Related]
12. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
Schoemaker R; Krauwinkel W; Elshoff JP; Stockis A
Epilepsy Res; 2024 May; 202():107332. PubMed ID: 38518434
[TBL] [Abstract][Full Text] [Related]
13. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
[TBL] [Abstract][Full Text] [Related]
14. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic (PBPK) modeling in children.
Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
[TBL] [Abstract][Full Text] [Related]
16. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
[TBL] [Abstract][Full Text] [Related]
17. Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.
Mulugeta Y; Barrett JS; Nelson R; Eshete AT; Mushtaq A; Yao L; Glasgow N; Mulberg AE; Gonzalez D; Green D; Florian J; Krudys K; Seo S; Kim I; Chilukuri D; Burckart GJ
J Clin Pharmacol; 2016 Nov; 56(11):1326-1334. PubMed ID: 27040726
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
McLeay SC; Green B; Treem W; Thyssen A; Mannaert E; Kimko H
Clin Pharmacokinet; 2014 Oct; 53(10):943-57. PubMed ID: 25168707
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics.
Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H
J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853
[TBL] [Abstract][Full Text] [Related]
20. A model-based approach to dose selection in early pediatric development.
Cella M; Gorter de Vries F; Burger D; Danhof M; Della Pasqua O
Clin Pharmacol Ther; 2010 Mar; 87(3):294-302. PubMed ID: 20107435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]